Cigarette smoke retention and bronchodilation in patients with COPD. A controlled randomized trial

Respiratory Medicine

Volumn 107, Issue 1, 2013, Pages 112-119

  Van Dijk, Wouter D ^a   Heijdra, Yvonne ^a   Lenders, Jacques W M ^a,b   Klerx, Walther ^c   Akkermans, Reinier ^a   Van Der Pouw, Anouschka ^d   Van Weel, Chris ^a   Scheepers, Paul T J ^a   Schermer, Tjard R J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Voedsel en Waren Autoriteit Netherlands   (Netherlands)

^d Alysis Medical Centre   (Netherlands)

Author keywords

COPD; Interaction; Smoke retention; Smoking

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CIGARETTE SMOKE; CIGARETTE TAR; FIBRINOGEN; NICOTINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKE RETENTION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INHALATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING AND SMOKING RELATED PHENOMENA;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRONCHODILATOR AGENTS; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; NICOTINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE; SMOKING; TARS; VITAL CAPACITY;

EID: 84871359412     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.09.019     Document Type: Article

References (29)

1. Global Strategy for the Diagnosis, Management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD). Available from: www.goldcopd.com [accessed August 2011].
2. A. Jemal, E. Ward, and Y. Hao Trends in the leading causes of death in the United States, 1970-2002 JAMA 294 10 2005 1255 1259
3. A.D. Lopez, K. Shibuya, and C. Rao Chronic obstructive pulmonary disease: current burden and future projections Eur Respir J 27 2006 397 412
4. W.M. Chatila, B.M. Thomashow, and O.A. Minai Comorbidities in chronic obstructive pulmonary disease Proc Am Thorac Soc 5 4 2008 549 555
5. S.M. Curkendall, C. DeLuise, and J.K. Jones Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients Ann Epidemiol 16 1 2006 63 70
6. K.K. Teo, S. Ounpuu, and S. Hawken Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study Lancet 368 9536 2006 647 658
7. R. Doll, R. Peto, and J. Boreham Mortality in relation to smoking: 50 years' observations on male British doctors BMJ 328 7455 2004 1519
8. T. Schermer, Y. Heijdra, and S. Zadel Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD Respir Med 101 6 2007 1355 1362
9. E.F. Ellerbeck, J.D. Mahnken, and A.P. Cupertino Effect of varying levels of disease management on smoking cessation: a randomized trial Ann Intern Med 150 7 2009 437 446
10. M. Cazzola, and M.G. Matera Novel long-acting bronchodilators for COPD and asthma Br J Pharmacol 155 3 2008 291 299
11. N.R. Anthonisen, J.E. Connett, and P.L. Enright Hospitalizations and mortality in the Lung Health Study Am J Respir Crit Care Med 166 3 2002 333 339
12. G.J. Rodrigo, J.A. Castro-Rodriguez, and L.J. Nannini Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis Respir Med 103 10 2009 1421 1429
13. B. Celli, M. Decramer, and S. Kesten Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 10 2009 948 955
14. S.R. Salpeter, T.M. Ormiston, and E.E. Salpeter Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis Chest 125 6 2004 2309 2321
15. P.M. Calverley, J.A. Anderson, and B. Celli Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease New Engl J Med 356 8 2007 775 789
16. S. Singh, Y.K. Loke, and P.L. Enright Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials BMJ 342 2011 d3215
17. W.D. van Dijk, Y. Heijdra, and P.T. Scheepers Interaction in COPD experiment (ICE): a hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease Med Hypotheses 74 2 2010 277 280
18. W.D. van Dijk, J.W. Lenders, and J. Holtman Bronchodilation and smoking interaction in COPD: a cohort pilot study to assess cardiovascular risk Respiration 83 2 2012 125 132 10.1159/000326921
19. W. van Dijk, P. Scheepers, and R. Cremers A method to study the effect of bronchodilators on smoke retention in COPD patients: study protocol for a randomized controlled trial Trials 12 1 2011 37
20. W.A. Pryor, K. Stone, and L.Y. Zang Fractionation of aqueous cigarette tar extracts: fractions that contain the tar radical cause DNA damage Chem Res Toxicol 11 5 1998 441 448
21. Y.H. Chan Randomised controlled trials (RCTs)-sample size: the magic number? Singapore Med J 44 4 2003 172 174
22. S. Feng, S.E. Plunkett, and K. Lam A new method for estimating the retention of selected smoke constituents in the respiratory tract of smokers during cigarette smoking Inhal Toxicol 19 2 2007 169 179
23. C. McGrath, N. Warren, and P. Biggs Real-time measurement of inhaled and exhaled cigarette smoke: implications for dose J Phys 2009 Conference Series 151:012018
24. C. Dickens, C. McGrath, and N. Warren Puffing and inhalation behaviour in cigarette smoking: implications for particle diameter and dose J Phys 2009 Conference series 151:012019
25. A.K. Armitage, M. Dixon, and B.E. Frost The effect of inhalation volume and breath-hold duration on the retention of nicotine and solanesol in the human respiratory tract and on subsequent plasma nicotine concentrations during cigarette smoking Contribut Tob Res 21 4 2004 240 249
26. A.K. Armitage, M. Dixon, and B.E. Frost The effect of tobacco blend additives on the retention of nicotine and solanesol in the human respiratory tract and on subsequent plasma nicotine concentrations during cigarette smoking Chem Res Toxicol 17 4 2004 537 544
27. R.R. Baker, and M. Dixon The retention of tobacco smoke constituents in the human respiratory tract Inhal Toxicol 18 4 2006 255 294
28. R. Nil, R. Buzzi, and K. Battig Effects of different cigarette smoke yields on puffing and inhalation: is the measurement of inhalation volumes relevant for smoke absorption? Pharmacol Biochem Behav 24 3 1986 587 595
29. J.P. Zacny, M.L. Stitzer, and F.J. Brown Human cigarette smoking: effects of puff and inhalation parameters on smoke exposure J Pharmacol Exp Ther 240 2 1987 554 564